Peihua Lu, MD, of Beijing Lu Daopei Institute of Hematology in China, stopped by the SOHO booth to speak with SOHO Insider during the 66th American Society of Hematology (ASH) Annual Meeting and Exposition.
The abstract (number 2075) was titled, “CD7-targeted CAR-T cell therapy shows promising efficacy and safety in treating refractory/relapsed peripheral T-cell lymphoma: phase I clinical trial,” and presented by Dr. Lu during ASH 2024.
“Our study highlights that CD7-positive heavy pretreated [refractory/relapsed peripheral T-cell lymphoma] patients could achieve a promising [complete remission] and safety profile after CD7-targeted CAR-T therapy, who otherwise have very limited therapy options,” the authors wrote in the ASH abstract.
